Antiangiogenic properties of cafestol, a coffee diterpene, in human umbilical vein endothelial cells

Biochemical and Biophysical Research Communications

Volumn 421, Issue 3, 2012, Pages 567-571

  Wang, Shuaiyu ^a,b   Yoon, Yeo Cho ^b   Sung, Mi Jeong ^b   Hur, Haeng Jeon ^b   Park, Jae Ho ^b  

^a University of Science and Technology (UST)   (South Korea)

^b Korea Food Research Institute   (South Korea)

Author keywords

Akt; Angiogenesis; Cafestol; FAK; Nitric oxide

Indexed keywords

ANGIOGENESIS INHIBITOR; CAFESTOL; DITERPENE; FOCAL ADHESION KINASE; NITRIC OXIDE; PROTEIN KINASE B;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COFFEE; DITERPENES; FOCAL ADHESION KINASE 1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84860663726     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.046     Document Type: Article

References (24)

1. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473(7347):298-307.
2. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257.
3. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438(7070):967-974.
4. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17(11):1359-1370.
5. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9(6):669-676.
6. Lechertier T., Hodivala-Dilke K. Focal adhesion kinase and tumour angiogenesis. J. Pathol. 2012, 226(2):404-412.
7. Cook K.M., Figg W.D. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J. Clin. 2010, 60(4):222-243.
8. George S.E., Ramalakshmi K., Mohan L.J. A perception on health benefits of coffee. Crit. Rev. Food. Sci. Nutr. 2008, 48(5):464-486.
9. Cavin C., Holzhaeuser D., Scharf G., et al. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem. Toxicol. 2002, 40(8):1155-1163.
10. Lee K.J., Choi J.H., Jeong H.G. Hepatoprotective and antioxidant effects of the coffee diterpenes kahweol and cafestol on carbon tetrachloride-induced liver damage in mice. Food Chem. Toxicol. 2007, 45(11):2118-2125.
11. Lee K.J., Jeong H.G. Protective effects of kahweol and cafestol against hydrogen peroxide-induced oxidative stress and DNA damage. Toxicol. Lett. 2007, 173(2):80-87.
12. Lee S.J., Namkoong S., Kim Y.M., et al. Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am. J. Physiol. Heart Circ. Physiol. 2006, 291(6):H2836-H2846.
13. Hanks S.K., Polte T.R. Signaling through focal adhesion kinase. Bioessays 1997, 19(2):137-145.
14. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 1998, 273(46):30336-30343.
15. Parenti A., Morbidelli L., Cui X.L., et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J. Biol. Chem. 1998, 273(7):4220-4226.
16. Noiri E., Hu Y., Bahou W.F., et al. Permissive role of nitric oxide in endothelin-induced migration of endothelial cells. J. Biol. Chem. 1997, 272(3):1747-1752.
17. Goligorsky M.S., Abedi H., Noiri E., et al. Nitric oxide modulation of focal adhesions in endothelial cells. Am. J. Physiol. 1999, 276(6 Pt 1):C1271-C1281.
18. Dimmeler S., Dernbach E., Zeiher A.M. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett. 2000, 477(3):258-262.
19. Dimmeler S., Fleming I., Fisslthaler B., et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399(6736):601-605.
20. Fulton D., Gratton J.P., McCabe T.J., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399(6736):597-601.
21. Medina M.A., Munoz-Chapuli R., Quesada A.R. Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. J. Cell Mol. Med. 2007, 11(3):374-382.
22. Quesada A.R., Medina M.A., Alba E. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays 2007, 29(11):1159-1168.
23. Mitra S.K., Mikolon D., Molina J.E., et al. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006, 25(44):5969-5984.
24. Shiojima I., Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 2002, 90(12):1243-1250.